Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 31Rituximab 22Vincristine 19Doxorubicin 17Filgrastim 15Prednisone 14Peripheral Blood Stem Cell Transplantation 14Etoposide 13Cytarabine 12Magnetic Resonance Spectroscopy 10fludarabine phosphate 9Radiotherapy 9Bortezomib 9Biopsy 9Cyclosporine 8Specimen Handling 7Methotrexate 7Dexamethasone 7X-Rays 6Vorinostat 6Phantoms, Imaging 6Leucovorin 6Lenalidomide 6tanespimycin 5sargramostim 5fludarabine 5bryostatin 1 5aldesleukin 5Nuclear Medicine Department, Hospital 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Non-Hodgkin × Antiemetics × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡